Inventiva S.A. – LSE:0RNK.L
Inventiva S.A. stock price today
Inventiva S.A. stock price monthly change
Inventiva S.A. stock price quarterly change
Inventiva S.A. stock price yearly change
Inventiva S.A. key metrics
Market Cap | 185.57M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -3.74 |
Revenue | 29.65M |
EBITDA | -166.52M |
Income | -164.7M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -561.52% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInventiva S.A. stock price history
Inventiva S.A. stock forecast
Inventiva S.A. financial statements
| Jun 2022 | 67K | -29.46M | -43979.1% |
|---|---|---|---|
| Dec 2022 | 12.11M | -24.80M | -204.82% |
| Jun 2023 | 1.90M | -55.26M | -2907.36% |
| Dec 2023 | 15.57M | -55.15M | -354.12% |
| 2025 | 19.64M | -72.95M | -371.41% |
|---|---|---|---|
| 2026 | 35.06M | -67.91M | -193.65% |
| 2027 | 84.05M | -49.10M | -58.42% |
| 2028 | 242.64M | 31.27M | 12.89% |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 116004000 | 70.52M | 60.8% |
|---|---|---|---|
| Dec 2022 | 116004000 | 70.52M | 60.8% |
| Jun 2023 | 70819000 | 78.48M | 110.83% |
| Dec 2023 | 69139000 | 101.59M | 146.94% |
| Jun 2022 | -26.22M | -268K | 13.95M |
|---|---|---|---|
| Dec 2022 | -18.70M | 9.13M | 23.31M |
| Jun 2023 | -45.23M | -7.70M | -2.15M |
| Dec 2023 | -36.38M | -29K | 31.23M |
Inventiva S.A. alternative data
| Aug 2023 | 109 |
|---|---|
| Sep 2023 | 109 |
| Oct 2023 | 109 |
| Nov 2023 | 117 |
| Dec 2023 | 117 |
| Jan 2024 | 117 |
| Feb 2024 | 117 |
| Mar 2024 | 117 |
| Apr 2024 | 117 |
| May 2024 | 120 |
| Jun 2024 | 120 |
| Jul 2024 | 120 |
Inventiva S.A. other data
| Insider | Compensation |
|---|---|
Mr. Frédéric Cren (1966) Co-Founder, Chief Executive Officer & Chairman | $373,580 |
Dr. Pierre Broqua (1962) Co-Founder, Chief Scientific Officer & Deputy Chief Executive Officer | $262,410 |
Mr. Jean Volatier Chief Financial Officer | |
Dr. Irena Konstantinova Head of Biology & Pharmacology | |
Mr. Nicolas Gueugnon Legal Director | |
Dr. Olivier Lacombe PH.D. Head of Pharmacokinetics | |
Dr. Kristina Meyer Head of Bus. Devel. | |
Ms. Nathalie Harroy Head of HR | |
Dr. Michael Cooreman Chief Medical Officer | |
Dr. Christian Montalbetti PH.D. Head of Chemistry |
-
What's the price of Inventiva S.A. stock today?
One share of Inventiva S.A. stock can currently be purchased for approximately $11.98.
-
When is Inventiva S.A.'s next earnings date?
Unfortunately, Inventiva S.A.'s (0RNK.L) next earnings date is currently unknown.
-
Does Inventiva S.A. pay dividends?
No, Inventiva S.A. does not pay dividends.
-
How much money does Inventiva S.A. make?
Inventiva S.A. has a market capitalization of 185.57M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 43.5% to 17.48M US dollars.
-
What is Inventiva S.A.'s stock symbol?
Inventiva S.A. is traded on the LSE under the ticker symbol "0RNK.L".
-
What is Inventiva S.A.'s primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Inventiva S.A.?
Shares of Inventiva S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Inventiva S.A.'s key executives?
Inventiva S.A.'s management team includes the following people:
- Mr. Frédéric Cren Co-Founder, Chief Executive Officer & Chairman(age: 59, pay: $373,580)
- Dr. Pierre Broqua Co-Founder, Chief Scientific Officer & Deputy Chief Executive Officer(age: 63, pay: $262,410)
- Mr. Jean Volatier Chief Financial Officer
- Dr. Irena Konstantinova Head of Biology & Pharmacology
- Mr. Nicolas Gueugnon Legal Director
- Dr. Olivier Lacombe PH.D. Head of Pharmacokinetics
- Dr. Kristina Meyer Head of Bus. Devel.
- Ms. Nathalie Harroy Head of HR
- Dr. Michael Cooreman Chief Medical Officer
- Dr. Christian Montalbetti PH.D. Head of Chemistry
-
Is Inventiva S.A. founder-led company?
Yes, Inventiva S.A. is a company led by its founders Mr. Frédéric Cren and Dr. Pierre Broqua.
-
How many employees does Inventiva S.A. have?
As Jul 2024, Inventiva S.A. employs 120 workers, which is 3% more then previous quarter.
-
When Inventiva S.A. went public?
Inventiva S.A. is publicly traded company for more then 8 years since IPO on 30 Mar 2017.
-
What is Inventiva S.A.'s official website?
The official website for Inventiva S.A. is inventivapharma.com.
-
How can i contact Inventiva S.A.?
Inventiva S.A. can be reached via phone at +33 3 80 44 75 00.
Inventiva S.A. company profile:
Inventiva S.A.
inventivapharma.comLSE
123
Medical - Pharmaceuticals
Healthcare
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Daix, 21121
:
ISIN: FR0013233012
:
